According to a new report published by
Allied Market Research, titled,"Varicella Live Vaccine Market by
Product, Application, and Provider: Global Opportunity Analysis and Industry
Forecast, 2018-2026," the global varicella live
vaccine market was valued at $2.71 billion in 2018, and is expected to reach
$4.22 billion by 2026, registering a CAGR of 5.7% from 2019 to 2026.
Viral infections can be prevented by
immunization and therefore, immunization is crucial. Varicella zoster is a virus
that causes diseases such as chicken pox and herpes zoster. However, these
infectious diseases can be prevented by the use of varicella live vaccines.
Varicella live vaccines are administered to both children and adults in a
pattern of two doses to ensure complete immunization. These vaccines contain a
weakened form of varicella zoster virus that is effective in creating immunity
against the same virus. There are two different types of varicella live
vaccines such as monovalent and combination varicella vaccines.
Request
Sample Report at: https://www.alliedmarketresearch.com/request-sample/3969
Rise in immunization programs worldwide is
the major factor that boost the growth of the varicella live vaccine market. In
addition, factors such as surge in awareness related to the use of varicella
live vaccines and increase in adoption of varicella vaccination across the
globe fuel the growth of the varicella live vaccine market. However, high
monetary inputs associated with manufacture of the products restrict the growth
of the market. Conversely, growth potential in emerging economies is expected
to create lucrative opportunities for the market during the forecast period.
The global varicella live vaccine market is
segmented based on product, application, and provider. On the basis of product,
the market is bifurcated into monovalent varicella vaccine and combination
varicella vaccine. By application, it is divided into chicken pox immunization,
herpes zoster immunization and measles, mumps, rubella and varicella (MMRV)
immunization.
The developing economies offer lucrative
opportunities for varicella live vaccine providers to expand their business.
The constantly evolving life science industry drives the growth of the market
in the developing economies such as India, China, and others.
For
Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/3969
Key Findings of
The Varicella Live Vaccine Market:
- Monovalent varicella vaccine occupied
two-thirds share of the global varicella live vaccine market in 2018
- The herpes zoster segment is anticipated
to grow with the highest CAGR throughout the forecast period
- The private segment accounted for
two-third share of the market in 2018
- Asia-Pacific is anticipated to grow at
the highest rate during the analysis period, followed by LAMEA
No comments:
Post a Comment